Product
Spiriva HandiHaler
1 clinical trial
2 indications
Indication
Pulmonary DiseaseIndication
Chronic ObstructiveClinical trial
A Single Dose, Placebo-controlled, Randomized, Double-blind, Double-dummy, Crossover Efficacy, Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder (5 μg and 10 μg), Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® (18 μg Tiotropium) in Patients With Chronic Obstructive Pulmonary Disease (COPD)Status: , Estimated PCD: 2006-06-04